MindImmune, a Cambridge, MA-based biotechnology company, has received a $5 million investment from Alzheimer’s Drug Discovery Foundation.
Read More:Rebar Raises $14M in Series A Funding
The company plans to use the funds to complete key translational studies, submit its IND, and support early clinical development planning.
This major funding highlights the growing scientific focus on immune-related processes in Alzheimer’s and positions MindImmune as a leader in a new wave of treatment innovation.
This award supports the ADDF’s goal of advancing promising research that could change Alzheimer’s treatments and shows increasing confidence in immune-focused approaches as a key area in neurodegenerative disease.
Alzheimer’s disease affects millions of people worldwide with harmful changes starting years or even decades before symptoms appear. While some treatments address key protein abnormalities growing evidence shows that immune system problems, and chronic brain inflammation play a major role in disease development. MITI-101 is designed to act early in these immune pathways, targeting processes that drive ongoing neuroinflammatory damage. By adjusting immune cell function, MindImmune aims to tackle a core part of neurodegeneration that has often been overlooked.
“Alzheimer’s disease is one of the most urgent and complex medical challenges,” said Stevin Zorn, Chief Science Officer of MindImmune. “Support from the ADDF allows us to explore immune biology in neurodegeneration and quickly move MITI-101 toward clinical trials. We are building on strong scientific evidence with the potential to change how this devastating disease is treated.”
“Progress in Alzheimer’s research requires bold strategies that tackle the disease’s underlying biology,” said Dr. Howard Fillit, Co-Founder and Chief Science Officer of the ADDF. “Our support of MindImmune, and its lead candidate, MITI-101, shows ADDF’s commitment to developing new therapies that target key drivers like neuroinflammation. Addressing these mechanisms is crucial for building a precision medicine approach to treat and eventually prevent Alzheimer’s.”
About MindImmune
MindImmune is a biotechnology company focused on developing immune based therapies for neurodegenerative diseases, including Alzheimer’s. By targeting the biological pathways that cause neuroinflammation and drive disease progression, MindImmune is creating a new class of treatments aimed at changing the course of neurodegeneration.
About The Alzheimer’s Drug Discovery Foundation (ADDF)
Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer’s Drug Discovery Foundation (ADDF) focuses on speeding the development of drugs to prevent, treat, and cure Alzheimer’s. The ADDF is the only public charity dedicated solely to Alzheimer’s drug research, using a venture philanthropy approach to support work in academia and biotech. Its efforts helped bring the first Alzheimer’s PET scan (Amyvid®) and blood test (PrecivityAD®) to market and have funded a strong, diverse drug pipeline. To date, ADDF has awarded nearly $400 million to 792 drug development, biomarker, and prevention programs across 21 countries.
Read More:Lux Aeterna Secures $10M in Seed Funding
